Evotec and Debiopharm Group™ to collaborate on development of new treatment for cancer

Evotec and Debiopharm Group™ to collaborate on development of new treatment for cancer

Evotec AG announced a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland. The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations. Discovery and pre-clinical development efforts will be driven by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

Read more…